While PET imaging with radionuclides such as F18 and Ga68 have proven to provide high quality diagnostic imaging, imaging with other radionuclides can be more challenging. Zr-89 is one such radionuclide. Although Zr-89 has advantageous labelling properties for cell imaging and the imaging of monoclonal antibodies, the radionuclide is non-ideal imaging qualities mostly due to […]
The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However, due to differences in clinical processes and insurance systems in each country, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe, […]
With the arrival of new therapeutic tracers, nuclear medicine has a new arsenal to treat metastatic bone pain. This presentation aims to give the keys to define the place of nuclear medicine among other treatment modalities (external beam therapy, medical treatment, chemotherapy). Learning Objectives: Refresh knowledge on the pathophysiology of pain and present the opportunities […]
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
more information coming soon Faculty Event Overview
European School of Multimodality Imaging & Therapy (ESMIT)
Schmalzhofgasse 26
1060 Vienna
Austria
phone +43 1 890 44 27
e-mail esmit@eanm.org
